Q1 Sales EUR 6.5 Million (+13%); continued double digit growth after profitable growth in 2010
(Thomson Reuters ONE) -
aap Implantate AG /
Q1 Sales EUR 6.5 Million (+13%); continued double digit growth after profitable
growth in 2010
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
According to preliminary figures, aap Implantate AG, a medical technology
company listed in the Frankfurt Stock Exchange's Prime Standard segment, totaled
in the first-quarter of the financial year 2011 sales of EUR 6.5 million
(previous year: EUR 5.8 million), which was a 14 percent increase on the
previous year's figure. With this sales growth, aap was able to continue the
positive trend of 2010 (adjusted sales growth on product level of 14%[1])
Consolidation of the two R&D sites in Dieburg and Obernburg was completed on
March 15, 2011 and will lead to additional gains in effectiveness and an
intensification of knowledge sharing and further cost reductions. With the
consolidation of Research & Development and production at the Dieburg site a
center of excellence for bone cement and cementing techniques has been created.
aap now has three centers of excellence. In addition to Dieburg, there is a
center of excellence for trauma in Berlin, while in 2010 a center of excellence
for contract manufacturing "medical devices/pharmaceuticals" known as EMCM
(European Medical Contract Manufacturing) was set up in Nijmegen, Netherlands.
At the end of the second quarter, aap plans the market launch of its innovative
WSG product line. The Management Board expects the WSG system to develop into a
growth carrier in its first year, making a major contribution toward improving
the company's Freshness Index. In the second quarter, Jason® G, the antibiotic-
impregnated collagen fleece, will also be launched.
aap has reached an advanced stage in negotiations with a customer label client
who would like to sell one of our trauma products in the U.S. market. A further
partnership is planned with a globally active orthopedics company on a customer
label contract in the cement segment.
aap plans to publish the full Q1 2011 on May 11, 2011.
This release contains forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
--------------------------------------------------------------------------------
[1] Adjusted sales growth 2010/2009 after eliminating the effects of the project
business in 2010/2009 and adjustments for the effects 2009 for the Analytics
division and other one-time effects. For further illustrations and calculation
details we refer to page 19 of the consolidated annual financial statement 2010.
______________________________________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a medical technology company that develops, manufactures and markets
biomaterials and implants for the areas Ortho/Trauma/Spine. Its product
portfolio includes bone cements, bone graft substitutes, antibiotic carriers,
and implants for fracture healing and joint replacement. In addition to its
Berlin HQ the Company has sites in Dieburg and Obernburg near Frankfurt am Main
and Nijmegen in the Netherlands. aap Implantate AG stock has been listed in the
Prime Standard segment of the Frankfurt Stock Exchange since May 16, 2003.
For inquiries please contact:
aap Implantate AG, Nanette Huedepohl, Head of Corporate Communications,
Lorenzweg 5, 12099 Berlin, Germany, Tel.: +49 30 7501 9133, fax:
+49 30 7501 9290, n.huedepohl(at)aap.de
For more details please visit www.aap.de
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1503441]
Unternehmensinformation / Kurzprofil:
Datum: 05.04.2011 - 10:04 Uhr
Sprache: Deutsch
News-ID 53169
Anzahl Zeichen: 5975
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Q1 Sales EUR 6.5 Million (+13%); continued double digit growth after profitable growth in 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
